Molnupiravir, a prodrug of the nucleoside derivative β-DN 4-hydroxycytidine (NHC), is
currently in clinical trials for COVID-19 therapy. However, the biochemical mechanisms …

RNA-dependent RNA polymerase (RdRp), also known as nsp12, is a key component in the
synthesis of viral ribonucleic acid (RNA) and is considered the primary target of nucleoside …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus
2 is an important target in current drug development efforts for the treatment of coronavirus …

Summary N4-hydroxycytidine (NHC), the active compound of the drug Molnupiravir, is
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …

Mutagenic ribonucleosides can act as broad-based antiviral agents. They are metabolized
to the active ribonucleoside triphosphate form and concentrate in genomes of RNA viruses …

Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts
antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …

Molnupiravir (MOV) is used to treat COVID‐19. In cells, MOV is converted to the
ribonucleoside analog N4‐hydroxycytidine (NHC) and incorporated into the SARS‐CoV‐2 …

In RNA viruses, a small increase in their mutation rates can be sufficient to exceed their
threshold of viability. Lethal mutagenesis is a therapeutic strategy based on the use of …

Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp)
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …